A safe and effective Chikungunya vaccine has been developed from an insect-specific virus that does not affect people.
Highlights:
- The first vaccine for Chikungunya has been developed from an insect-specific virus.
- The vaccine was found to be safe and effective to produce a strong immune defense against the virus.
- A single shot of vaccine produced antibodies that lasted for 290 days.
Eilat Virus as a Vaccine for Chikungunya
Vaccine development is based on two factors- the first is safety, and the other is how quickly the vaccine works. Traditionally, live-attenuated vaccines were developed from weakened live pathogens. Those vaccines offered rapid and durable immunity but reduced safety.The research team at The University of Texas Medical Branch used the Eilat virus as a vaccine platform to overcome the trade-offs that were seen while using live-attenuated or inactivated vaccines. The Eilat virus only infects insects and has no effect on people.
An Eilat virus clone was used to design a hybrid virus-based vaccine containing Chikungunya structural proteins.
The newly developed Chikungunya vaccine was structurally identical to natural Chikungunya virus. However, the difference is that the hybrid virus replicates in mosquito cells, but, it cannot replicate in mammals.
Efficacy of the Newly Developed Chikungunya Vaccine
The vaccine was found to provide complete protection against the Chikungunya virus in two different mouse models. However, in the non-human primates, there was neither evidence of the virus in the blood nor symptoms of Chikungunya.
The findings of the study are detailed in Nature Medicine.
Chikungunya
Chikungunya is a mosquito-borne disease that causes fever and joint pain. Some of the other symptoms of Chikungunya include fatigue, muscle pain, headache, and rash. Some individuals may recover within a week, but many develop long-term joint pain.
Facts
- Chikungunya-causing mosquitoes are Aedes aegypti and Aedes albopictus.
- The onset of illness after the bite of an infected mosquito is between 4 and eight days, but can also range from 2 to 12 days.
- Chikungunya cases have been reported in over 60 countries in Asia, Africa, Europe and the Americas.
- There is no commercial vaccine or anti-viral treatment for chikungunya.
- In 2015, more than 1.4 million chikungunya cases were reported in the Caribbean Islands, in Latin American countries, and in the United States.
- A total of 12,255 Chikungunya cases were reported in India in 2016.
- Wear long sleeved shirts to prevent mosquito bite
- Use repellent sprays and creams
- Use mosquito nets
- Keep the surroundings clean to prevent breeding of mosquitoes.
- Chikungunya Virus - (http://www.mayoclinic.org/diseases-conditions/infectious-diseases/expert-answers/what-is-chikungunya-fever/faq-20109686)
- What is chikungunya fever, and should I be worried? - (https://www.cdc.gov/chikungunya/symptoms/)